Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Nguyen on the Optimal Duration of ADT in High-Risk Prostate Cancer

September 23rd 2020

Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.

Dr. Shore on the Objective of the HERO Trial in Advanced Prostate Cancer

September 23rd 2020

Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.

Dr. Choudhury on Treatment Goals in Nonmetastatic CRPC

September 23rd 2020

Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.

VERU-111 Demonstrates Preliminary Viability in Pretreated mCRPC

September 23rd 2020

Continuous administration of the novel tubulin inhibitor VERU-111 proved to be safe and demonstrated antitumor activity, evidenced by prostate-specific antigen reductions, objective tumor responses, and durable activity, in men with previously treated metastatic castration-resistant prostate cancer.

Dr. Choudhury on the Safety Profiles of Antiandrogens in Nonmetastatic CRPC

September 22nd 2020

Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Hussain on the Safety Profile of Olaparib in the PROfound Trial in mCRPC

September 22nd 2020

Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.

Dr. Trinh on Re-Establishing Standard Surgical Procedures in Prostate Cancer

September 22nd 2020

Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.

Dr. Trinh on the Impact of the COVID-19 Pandemic on Prostate Cancer

September 21st 2020

Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.

Dr. Choudhury on the Different States of Nonmetastatic CRPC

September 21st 2020

Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.

Dr. Nguyen on Future Research in High-Risk Prostate Cancer

September 21st 2020

Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.

Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate Cancer

September 21st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for olaparib for approval as a monotherapy for metastatic castration-resistant prostate cancer and BRCA1/2 mutations who have progressed after previous therapy with a new hormonal agent.

Novel BiTE Immuno-Oncology Therapy Appears Safe with Preliminary Efficacy in mCRPC

September 21st 2020

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Frontline Ipatasertib/Abiraterone Regimen Shows Superior Radiographic PFS in PTEN-Loss mCRPC

September 20th 2020

Ipatasertib combined with abiraterone acetate plus prednisone led to a significantly superior radiographic progression-free survival and antitumor activity compared with placebo plus abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer with PTEN loss.

Updated Findings Show Olaparib Prolongs OS in Men with mCRPC

September 20th 2020

Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.

Dr. Trinh on Prostate Cancer Treatment During the COVID-19 Crisis

September 17th 2020

Quoc-Dien Trinh, MD, discusses current strategies on the treatment of patients with high-risk prostate cancer during the COVID-19 crisis.

Nivolumab/Ipilimumab Combo Induces Improved Responses in Chemo-Naïve mCRPC

September 17th 2020

The combination of nivolumab and ipilimumab demonstrated improved responses in a cohort of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer compared with a cohort of chemotherapy-exposed patients.

Dr. Nguyen on the Utility of a Brachytherapy Boost in the ASCENDE-RT Trial

September 16th 2020

Paul L. Nguyen, MD, discusses the utility of adding a brachytherapy boost to radiation therapy in the ASCENDE-RT trial.

Dr. McGregor on Future Research in mCRPC

September 15th 2020

Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.

Focal Ultrasound Ablation Demonstrates Utility as Primary Therapy in Prostate Cancer

September 15th 2020

Hemigland high-intensity focused ultrasound ablation of the prostate was found to be a safe and effective primary treatment for men with localized prostate cancer, leading to continence preservation and suitable short-term disease control.

FDA Grants Fast Track Status to EPI-7386 in mCRPC

September 14th 2020

The FDA granted a fast track designation to the highly-selective N-terminal domain inhibitor EPI-7386 for the treatment of adult patients with metastatic castration-resistant prostate cancer who are resistant to standard-of-care options.